Monotherapy With Anti-CD70 Antibody Causes Long-Term Mouse Cardiac Allograft Acceptance With Induction of Tolerogenic Dendritic Cells. 2020

Jing Zhao, and Weitao Que, and Xiaoxiao Du, and Masayuki Fujino, and Naotsugu Ichimaru, and Hisashi Ueta, and Nobuko Tokuda, and Wen-Zhi Guo, and Piotr Zabrocki, and Hans de Haard, and Norio Nonomura, and Xiao-Kang Li
Division of Transplantation Immunology, National Research Institute for Child Health and Development, Tokyo, Japan.

Allograft rejection has been an obstacle for the long-term survival of patients. CD70, a tumor necrosis factor (TNF) family member critically expressed on antigen-presenting cells and strongly but transiently up-regulated during lymphocyte activation, represents an important co-stimulatory molecule that induces effective T cell responses. We used a mouse heterotopic cardiac transplantation model to evaluate the effects of monotherapy with the antibody targeting mouse CD70 (FR70) on transplantation tolerance and its immunoregulatory activity. FR70-treated C3H recipient mice permanently accepted B6 fully mismatched cardiac allografts. Consistent with the graft survival, the infiltration of CD8+ T cells in the graft was reduced, dendritic cells were differentiated into a tolerogenic status, and the number of regulatory T cells was elevated both in the graft and the recipient's spleen. In addition, naïve C3H given an adoptive transfer of spleen cells from the primary recipients with FR70 treatment accepted a heart graft from a matching B6 donor but not third-party BALB/c mice. Our findings show that treatment with FR70 induced regulatory cells and inhibited cytotoxic T cell proliferation, which led to long-term acceptance of mouse cardiac allografts. These findings highlight the potential role of anti-CD70 antibodies as a clinically effective treatment for allograft rejection.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D003713 Dendritic Cells Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION). Dendritic Cells, Interdigitating,Interdigitating Cells,Plasmacytoid Dendritic Cells,Veiled Cells,Dendritic Cells, Interstitial,Dendritic Cells, Plasmacytoid,Interdigitating Dendritic Cells,Interstitial Dendritic Cells,Cell, Dendritic,Cell, Interdigitating,Cell, Interdigitating Dendritic,Cell, Interstitial Dendritic,Cell, Plasmacytoid Dendritic,Cell, Veiled,Cells, Dendritic,Cells, Interdigitating,Cells, Interdigitating Dendritic,Cells, Interstitial Dendritic,Cells, Plasmacytoid Dendritic,Cells, Veiled,Dendritic Cell,Dendritic Cell, Interdigitating,Dendritic Cell, Interstitial,Dendritic Cell, Plasmacytoid,Interdigitating Cell,Interdigitating Dendritic Cell,Interstitial Dendritic Cell,Plasmacytoid Dendritic Cell,Veiled Cell
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D013154 Spleen An encapsulated lymphatic organ through which venous blood filters.
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic
D016027 Heart Transplantation The transference of a heart from one human or animal to another. Cardiac Transplantation,Grafting, Heart,Transplantation, Cardiac,Transplantation, Heart,Cardiac Transplantations,Graftings, Heart,Heart Grafting,Heart Graftings,Heart Transplantations,Transplantations, Cardiac,Transplantations, Heart
D016130 Immunophenotyping Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry. Lymphocyte Immunophenotyping,Lymphocyte Subtyping,Immunologic Subtyping,Immunologic Subtypings,Lymphocyte Phenotyping,Subtyping, Immunologic,Subtypings, Immunologic,Immunophenotyping, Lymphocyte,Immunophenotypings,Immunophenotypings, Lymphocyte,Lymphocyte Immunophenotypings,Lymphocyte Phenotypings,Lymphocyte Subtypings,Phenotyping, Lymphocyte,Phenotypings, Lymphocyte,Subtyping, Lymphocyte,Subtypings, Lymphocyte
D016176 T-Lymphocyte Subsets A classification of T-lymphocytes, especially into helper/inducer, suppressor/effector, and cytotoxic subsets, based on structurally or functionally different populations of cells. T-Cell Subset,T-Cell Subsets,T-Lymphocyte Subset,Subset, T-Cell,Subset, T-Lymphocyte,Subsets, T-Cell,Subsets, T-Lymphocyte,T Cell Subset,T Cell Subsets,T Lymphocyte Subset,T Lymphocyte Subsets

Related Publications

Jing Zhao, and Weitao Que, and Xiaoxiao Du, and Masayuki Fujino, and Naotsugu Ichimaru, and Hisashi Ueta, and Nobuko Tokuda, and Wen-Zhi Guo, and Piotr Zabrocki, and Hans de Haard, and Norio Nonomura, and Xiao-Kang Li
August 1993, Transplantation,
Jing Zhao, and Weitao Que, and Xiaoxiao Du, and Masayuki Fujino, and Naotsugu Ichimaru, and Hisashi Ueta, and Nobuko Tokuda, and Wen-Zhi Guo, and Piotr Zabrocki, and Hans de Haard, and Norio Nonomura, and Xiao-Kang Li
December 2010, Transplantation,
Jing Zhao, and Weitao Que, and Xiaoxiao Du, and Masayuki Fujino, and Naotsugu Ichimaru, and Hisashi Ueta, and Nobuko Tokuda, and Wen-Zhi Guo, and Piotr Zabrocki, and Hans de Haard, and Norio Nonomura, and Xiao-Kang Li
August 1996, Transplantation proceedings,
Jing Zhao, and Weitao Que, and Xiaoxiao Du, and Masayuki Fujino, and Naotsugu Ichimaru, and Hisashi Ueta, and Nobuko Tokuda, and Wen-Zhi Guo, and Piotr Zabrocki, and Hans de Haard, and Norio Nonomura, and Xiao-Kang Li
December 2019, International immunopharmacology,
Jing Zhao, and Weitao Que, and Xiaoxiao Du, and Masayuki Fujino, and Naotsugu Ichimaru, and Hisashi Ueta, and Nobuko Tokuda, and Wen-Zhi Guo, and Piotr Zabrocki, and Hans de Haard, and Norio Nonomura, and Xiao-Kang Li
January 2011, Cellular immunology,
Jing Zhao, and Weitao Que, and Xiaoxiao Du, and Masayuki Fujino, and Naotsugu Ichimaru, and Hisashi Ueta, and Nobuko Tokuda, and Wen-Zhi Guo, and Piotr Zabrocki, and Hans de Haard, and Norio Nonomura, and Xiao-Kang Li
August 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation,
Jing Zhao, and Weitao Que, and Xiaoxiao Du, and Masayuki Fujino, and Naotsugu Ichimaru, and Hisashi Ueta, and Nobuko Tokuda, and Wen-Zhi Guo, and Piotr Zabrocki, and Hans de Haard, and Norio Nonomura, and Xiao-Kang Li
April 2001, Transplantation,
Jing Zhao, and Weitao Que, and Xiaoxiao Du, and Masayuki Fujino, and Naotsugu Ichimaru, and Hisashi Ueta, and Nobuko Tokuda, and Wen-Zhi Guo, and Piotr Zabrocki, and Hans de Haard, and Norio Nonomura, and Xiao-Kang Li
May 2016, Immunology,
Jing Zhao, and Weitao Que, and Xiaoxiao Du, and Masayuki Fujino, and Naotsugu Ichimaru, and Hisashi Ueta, and Nobuko Tokuda, and Wen-Zhi Guo, and Piotr Zabrocki, and Hans de Haard, and Norio Nonomura, and Xiao-Kang Li
April 2004, Seminars in immunology,
Jing Zhao, and Weitao Que, and Xiaoxiao Du, and Masayuki Fujino, and Naotsugu Ichimaru, and Hisashi Ueta, and Nobuko Tokuda, and Wen-Zhi Guo, and Piotr Zabrocki, and Hans de Haard, and Norio Nonomura, and Xiao-Kang Li
January 2010, International surgery,
Copied contents to your clipboard!